home / stock / ibrx / ibrx news


IBRX News and Press, ImmunityBio Inc. From 05/11/23

Stock Information

Company Name: ImmunityBio Inc.
Stock Symbol: IBRX
Market: NASDAQ
Website: immunitybio.com

Menu

IBRX IBRX Quote IBRX Short IBRX News IBRX Articles IBRX Message Board
Get IBRX Alerts

News, Short Squeeze, Breakout and More Instantly...

IBRX - ImmunityBio crashes 57% after FDA snub for cancer therapy

2023-05-11 07:44:31 ET ImmunityBio ( NASDAQ: IBRX ) lost ~57% in the pre-market trading Thursday after disclosing that the FDA rejected a marketing application for its product candidate Anktiva as a combination therapy for a type of bladder cancer. Issuing a so-called comp...

IBRX - The 7 Most Undervalued Growth Stocks for Your May Buy List

2023-05-08 06:00:39 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips With short sellers viciously attacking many popular stocks and Wall Street worrying too much about the macroeconomic outlook, there are a multitude of undervalued growth stocks for ...

IBRX - IBRX, TRUP and BAK among mid-day movers

2023-05-05 13:18:14 ET Gainers: Nanobiotix S.A. NBTX +217% . Minim ( MINM ) +120% . PacWest Bancorp PACW +81% . Western Alliance Bancorporation WAL +48% . Baosheng Media Group Holdings ( BAOS ) +43% . Braskem ( BAK ) +41% . I...

IBRX - Pfizer, GSK, AbbVie among pharmas set to rise with May catalysts

2023-04-29 16:00:00 ET With the first trading day in May coming on Monday, many pharmaceutical companies will be hoping their returns fare better than they did in April. The iShares U.S. Pharmaceuticals ETF ( IHE ) returned a paltry 1.6% in April. The ETF's top two holdings are ...

IBRX - National Multicenter Trial Opens to Study ImmunityBio's Tri-Ad5 Cancer Vaccines Plus N-803 to Prevent Cancer in People with Lynch Syndrome

The Phase 2b cancer vaccine trial will study a multiple vaccination approach called ‘Tri-Ad5’ that uses three ImmunityBio vaccines in combination with the company’s IL-15 superagonist N-803, to potentially reduce the risk of developing colorectal and other cancers in patients...

IBRX - ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong Delivers the Packard Lecture at Uniformed Services University

ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced that Executive Chairman and Global Chief Scientific and Medical Officer Patrick Soon-Shiong, M.D., has been invited to deliver the 2023 David Packard Award Lecture at the Uniformed Services University ...

IBRX - 3 Stocks to Buy That Could Be the Next Biotech Breakthrough

2023-04-16 12:08:24 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In general, biotech stocks are not ideal for conservative investors. The companies in search of the next medical breakthrough are inherently risky. If they fail, their stocks can languish a...

IBRX - IBRX, SANA and TPST among mid-day movers

2023-04-13 13:06:24 ET Gainers: CXApp ( CXAI ) +194% . Ocean Biomedical ( OCEA ) +50% . Consolidated Communications Holdings ( CNSL ) +41% . Amesite ( AMST ) +34% . SMX (Security Matters) Public Limited Company ( SMX ) +34% . ...

IBRX - ImmunityBio: FDA Approval Potential In May Of 2023

2023-04-12 16:08:42 ET Summary ImmunityBio, Inc. has a PDUFA date of May 23, 2023, for potential FDA approval of N-803 + BCG for the treatment of patients with BCG-unresponsive CIS non-muscle invasive bladder cancer. It is said that the global bladder cancer market could reach $11...

IBRX - 7 Top Penny Stocks Under $5; Time To Buy Now?

2023-03-29 11:28:16 ET With so much volatility in the stock market today, you may consider penny stocks an option. These stocks are typically priced under $5 and are known for extreme price fluctuations. They are also known for their potential for high returns. With that, they come with sig...

Previous 10 Next 10